For: | Ueno M, Takeda H, Takai A, Seno H. Risk factors and diagnostic biomarkers for nonalcoholic fatty liver disease-associated hepatocellular carcinoma: Current evidence and future perspectives. World J Gastroenterol 2022; 28(27): 3410-3421 [PMID: 36158261 DOI: 10.3748/wjg.v28.i27.3410] |
---|---|
URL: | https://www.wjgnet.com/2220-315x/full/v28/i27/3410.htm |
Number | Citing Articles |
1 |
Masayuki Ueno, Takahisa Kayahara, Hiroyuki Takabatake, Youichi Morimoto, Motowo Mizuno. Clinical characteristics and diagnostic process of nonalcoholic fatty liver disease-associated hepatocellular carcinoma. Kanzo 2023; 64(3): 122 doi: 10.2957/kanzo.64.122
|
2 |
Marlene Sophia Kohlhepp, Hanyang Liu, Frank Tacke, Adrien Guillot. The contradictory roles of macrophages in non-alcoholic fatty liver disease and primary liver cancer—Challenges and opportunities. Frontiers in Molecular Biosciences 2023; 10 doi: 10.3389/fmolb.2023.1129831
|
3 |
Kainan Zhang, Mengsi Yu, Hui Liu, Zhao Hui, Ning Yang, Xiaojuan Bi, Li Sun, RenYong Lin, Guodong Lü. Upregulated TUBG1 expression is correlated with poor prognosis in hepatocellular carcinoma. PeerJ 2022; 10: e14415 doi: 10.7717/peerj.14415
|
4 |
Carmelo Laface, Girolamo Ranieri, Felicia Maria Maselli, Francesca Ambrogio, Caterina Foti, Michele Ammendola, Marigia Laterza, Gerardo Cazzato, Riccardo Memeo, Giovanni Mastrandrea, Marco Lioce, Palma Fedele. Immunotherapy and the Combination with Targeted Therapies for Advanced Hepatocellular Carcinoma. Cancers 2023; 15(3): 654 doi: 10.3390/cancers15030654
|